（文章来源：证券日报） 证券日报网讯 12月2日，爱朋医疗在互动平台回答投资者提问时表示，公司与东部战区总医院在疼痛管 理微电脑注药泵系列产品上已产生业务合作，业绩占比较小。在脑机接口领域暂未与其合作。敬请广大 投资者理性决策，谨慎投资，注意投资风险。 ...

Group 1 - The company, Aipeng Medical, has developed non-invasive brain-computer interface products, specifically an ADHD behavior management system and a treatment system for refractory insomnia [2] - There are corresponding charging directories for ADHD behavior treatment and refractory insomnia treatment in hospitals [2] - Regions such as Hubei, Zhejiang, and Jiangsu have introduced medical service pricing projects related to brain-computer interfaces, which will accelerate the clinical practice and application of these technologies [2]

Core Viewpoint - Aipeng Medical (300753) is actively engaging with favorable policies for the brain-computer interface industry, aiming to leverage these opportunities for business growth [1] Group 1: Policy Support - The Minhang District has tailored specific policies to support the brain-computer interface industry, focusing on three main areas of robust support [1] - Key financial incentives include subsidies for leading companies up to 20 million yuan, annual R&D funding of up to 2 million yuan for three consecutive years, and awards for competition-winning projects up to 2 million yuan [1] - Significant platform construction can receive subsidies up to 50 million yuan, along with rent reductions of 100%, 50%, and 25% [1] Group 2: Company Response - Aipeng Medical acknowledges the importance of national and regional policies related to brain-computer interfaces and is committed to seizing these policy opportunities to enhance its business development [1]

Core Viewpoint - The company, Aipeng Medical (300753.SZ), is focusing on non-invasive brain-computer interface products, specifically an ADHD behavior management system and a treatment system for refractory insomnia [1] Group 1: Product Development - The company has developed non-invasive brain-computer interface products aimed at managing ADHD behavior and treating refractory insomnia [1] - Both ADHD behavior management and refractory insomnia treatment have corresponding fee schedules in hospitals [1] Group 2: Policy and Market Environment - Regions such as Hubei, Zhejiang, and Jiangsu have introduced medical service pricing projects related to brain-computer interfaces [1] - Relevant policies are expected to accelerate the clinical practice and application of brain-computer interfaces [1]

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：贵司与东部战区总医院有业务往来吗？ 爱朋医疗（300753.SZ）12月2日在投资者互动平台表示，公司与东部战区总医院在疼痛管理微电脑注药 泵系列产品上已产生业务合作，业绩占比较小。在脑机接口领域暂未与其合作。敬请广大投资者理性决 策，谨慎投资，注意投资风险。 ...

Core Insights - The brain-computer interface (BCI) industry in China is expected to enter a significant development phase by 2025, driven by strong policy support and capital investment [1][5][6] - The BCI sector has seen substantial investment activity, with 28 financing rounds completed in 2023, totaling over 5 billion yuan [1] - The A-share market has recognized BCI as a hot investment trend, with the BCI concept index rising by 52.13% over the past year, significantly outperforming the Shanghai and Shenzhen 300 index [1] Policy Support - The "14th Five-Year Plan" emphasizes BCI as one of the six key future industries, with a clear timeline for technological breakthroughs and industry development by 2027 and 2030 [5][6] - In July, a joint initiative from seven departments outlined strategies for BCI innovation and development, aiming to establish a robust industry ecosystem [5] - Shanghai has proactively developed a BCI action plan, targeting clinical applications and technological advancements by 2027 and 2030 [6] Market Performance - The BCI concept index (8841700.WI) has shown a remarkable increase, with notable stocks like Innovation Medical and Hanwei Technology experiencing gains of 170% and 139.48% respectively [2][1] - A total of 24 A-share companies are involved in the BCI sector, with an average revenue of 3.43 billion yuan and an average net profit of 431 million yuan for the first three quarters of the year [11] Industry Landscape - The BCI industry in China is rapidly evolving, with over 800 core enterprises identified, positioning China among the leading countries in this field [8] - Recent clinical trials, including the first invasive clinical trial in China, indicate significant advancements in BCI technology [8][9] - The launch of the "North Brain No. 1" GCP multi-center clinical trial marks a new phase in large-scale clinical validation of BCI systems [9] Company Developments - Companies like Lepu Medical and Aipeng Medical are actively pursuing commercialization of BCI products, with Lepu focusing on deep brain stimulation devices and Aipeng on EEG collection products [12][13] - Aipeng Medical has established a joint laboratory for ADHD treatment, indicating a focus on integrating BCI technology into clinical applications [13] - Recent regulatory changes, including the establishment of a "green channel" for insurance coding of innovative medical products, are expected to accelerate the clinical application of BCI technologies [13]

证券日报网讯爱朋医疗（300753）11月26日在互动平台回答投资者提问时表示，公司内部构建了系统性 战略导向型人才培养和激励体系，未来公司将根据经营情况，积极研究并适时开展股权激励等措施。 ...

格隆汇11月26日丨爱朋医疗(300753.SZ)在互动平台表示，公司暂无创新药相关研发或代销。 ...

Core Viewpoint - Aipeng Medical (300753) is actively exploring new equity incentive mechanisms in response to the growing focus on brain-computer interface technology and its own strategic initiatives in this area [1] Group 1: Company Initiatives - Aipeng Medical has previously implemented a three-year restricted stock incentive plan, which concluded in 2021 [1] - The company is currently accelerating its efforts in the brain-computer interface innovation business [1] Group 2: Future Plans - Aipeng Medical is developing a systematic strategic talent cultivation and incentive system [1] - The company plans to research and potentially implement new equity incentive measures based on its operational conditions in the future [1]

Group 1 - The core viewpoint of the news is that Aipeng Medical's stock has experienced significant fluctuations, with a year-to-date increase of 51.84% but a recent decline of 13.16% over the past five trading days [2] - As of November 19, Aipeng Medical's stock price was 26.67 yuan per share, with a market capitalization of 3.362 billion yuan [1] - The company has seen a net outflow of main funds amounting to 639.98 million yuan, with large orders accounting for 11.36% of total buying and 22.68% of total selling [1] Group 2 - Aipeng Medical's main business revenue composition includes 59.73% from pain management products, 29.40% from nasal and upper airway products, and 10.87% from other sources [2] - The company has been listed on the stock market since December 13, 2018, and is located in Rudong County, Jiangsu Province [2] - As of September 30, the number of shareholders decreased by 31.76% to 22,100, while the average circulating shares per person increased by 46.51% to 3,972 shares [3] Group 3 - For the period from January to September 2025, Aipeng Medical reported operating revenue of 252 million yuan, a year-on-year decrease of 8.41%, and a net profit attributable to the parent company of -11.4842 million yuan, a decrease of 401.64% [3] - The company has distributed a total of 113 million yuan in dividends since its A-share listing, with 16.3862 million yuan distributed over the past three years [4]